Search results for "Endocrine Tumor"

showing 10 items of 74 documents

Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and indivi…

2022

Background and aims: Therapy and prognosis of pancreatic neuroendocrine tumors (PanNETs) are strictly related to the Ki-67 index, which defines tumor grading. The criterion standard for the assessment of grading of PanNETs is EUS-guided FNA (EUS-FBAFNA) or EUS-guided fine-needle biopsy sampling (EUS-FNB). Because data on diagnostic accuracy of EUS-FNA and EUS-FNB are heterogeneous, we aimed to analyze the variability in concordance between EUS grading and surgical grading. Methods: The MEDLINE, SCOPUS, and EMBASE databases were searched until November 2021 to identify studies reporting the concordance rate between EUS grading and surgical grading. The study was conducted in accordance with …

Pancreatic NeoplasmspancreaNeuroendocrine TumorsKi-67 Antigenendoscopic ultrasoundGastroenterologyKi-67HumansReproducibility of ResultsRadiology Nuclear Medicine and imagingEndoscopic Ultrasound-Guided Fine Needle Aspirationneuroendocrine tumorGastrointestinal Endoscopy
researchProduct

Evaluation of polysialic acid in the diagnosis of Wilms' tumor. A comparative study on urinary tract tumors and non-neuroendocrine tumors.

1988

The polysialic acid moiety of the neural cell adhesion molecule has been shown to represent an onco-developmental antigen which can be detected in both embryonic human kidney and Wilms’ tumor but not in normal adult human kidney. In the present comparative study, Wilms’ tumors, clear cell (bone-metastasizing) sarcomas of kidney, cystic nephromas, renal cell carcinomas, transitional cell carcinomas and papillomas of the renal pelvis, ureter and urinary bladder (as well normal transitional epithelium from these regions), Ewing sarcomas, hepatoblastomas, rhabdomyosarcomas, and carcinomas of the stomach, colon, exocrine pancreas, lung, and esophagus, were investigated immunohistochemically for …

Pathologymedicine.medical_specialtyKidneyUrologic NeoplasmsPolysialic acidImmunoblottingAntibodies MonoclonalWilms' tumorGeneral MedicineBiologyNeuroendocrine tumorsTransitional epitheliummedicine.diseaseImmunohistochemistryWilms TumorKidney NeoplasmsMicemedicine.anatomical_structuremedicineBiomarkers TumorSialic AcidsAnimalsNeural cell adhesion moleculeRenal pelvisClear cellVirchows Archiv. B, Cell pathology including molecular pathology
researchProduct

Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours

2021

Abstract Aim Gallium-68-labelled inhibitors of the fibroblast activation protein (FAPi) enable positron emission tomography/computed tomography (PET/CT) imaging of fibroblast activation. We evaluated if [68Ga]Ga-DATA5m.SA.FAPi PET/CT is related to Ki-67 as a marker of tumour aggressiveness in patients with liver metastases of NET. Methods Thirteen patients with liver metastases of a histologically confirmed NET who underwent PET/CT with [68Ga]Ga-DATA5m.SA.FAPi, [18F]FDG and [68Ga]Ga-DOTA-TOC were retrospectively analyzed. PET-positive liver tumour volumes were segmented for calculation of volume, SUVmax and PET-positive tumour fraction (TF). PET parameters were correlated with Ki-67. Result…

Pathologymedicine.medical_specialtyProliferation index030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicineFibroblast activation protein alphaPositron Emission Tomography Computed TomographymedicineHumansRadiology Nuclear Medicine and imagingIn patientFibroblastGrading (tumors)Retrospective StudiesPET-CTbiologymedicine.diagnostic_testbusiness.industryLiver NeoplasmsGeneral MedicineFibroblastsNeuroendocrine TumorsKi-67 Antigenmedicine.anatomical_structurePositron emission tomography030220 oncology & carcinogenesisKi-67biology.proteinbusinessNuklearmedizin - NuclearMedicine
researchProduct

The 2021 WHO Classification of Tumors of the Thymus and Mediastinum: What Is New in Thymic Epithelial, Germ Cell, and Mesenchymal Tumors?

2022

Abstract This overview of the fifth edition of the WHO classification of thymic epithelial tumors (including thymomas, thymic carcinomas, and thymic neuroendocrine tumors [NETs]), mediastinal germ cell tumors, and mesenchymal neoplasms aims to (1) list established and new tumor entities and subtypes and (2) focus on diagnostic, molecular, and conceptual advances since publication of the fourth edition in 2015. Diagnostic advances are best exemplified by the immunohistochemical characterization of adenocarcinomas and the recognition of genetic translocations in metaplastic thymomas, rare B2 and B3 thymomas, and hyalinizing clear cell carcinomas. Advancements at the molecular and tumor biolog…

Pulmonary and Respiratory MedicinePathologymedicine.medical_specialtyLung NeoplasmsThymomaThymomaAdenocarcinomaNeuroendocrine tumorsWorld Health OrganizationThymic carcinoma03 medical and health sciences0302 clinical medicineGerm cell tumormedicineHumansGerm cell tumor; NET G3; Thymic carcinoma; Thymic neuroendocrine tumor; Thymoma; WHO classificationThymic carcinoma030304 developmental biologyWHO classification0303 health sciencesbusiness.industryMesenchymal stem cellMediastinumMediastinumThymus Neoplasmsmedicine.disease3. Good healthThymic neuroendocrine tumorGerm Cellsmedicine.anatomical_structureOncology030220 oncology & carcinogenesisGerm cell tumorsNET G3businessClear cellGerm cellJournal of Thoracic Oncology
researchProduct

A single-institution retrospective analysis of metachronous and synchronous metastatic bronchial neuroendocrine tumors

2018

Background: Broncho-pulmonary neuroendocrine tumors (bpNETs) are rare malignancies and there is no consensus on therapeutical management of metastatic disease and follow-up after radical resection. Methods: Clinical records of patients with a cytological or histological diagnosis of bpNETs and distant metastases (metachronous or synchronous), evaluated at the European Institute of Oncology between 1997 and 2014, were retrospectively analyzed. Data on patient demographics, pathology, imaging exams, surgical and non-surgical treatments were collected. P value descriptive data, uni- and multi-variate survival analysis were generated for all variables. Results: With a median follow-up of 53 [9–…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyMultivariate analysisSettore MED/06 - Oncologia MedicaPopulationDisease030204 cardiovascular system & hematologyNeuroendocrine tumorsCarcinoid tumor; Neoplasm metastasis; Neuroendocrine tumors (NETs); Recurrence; Pulmonary and Respiratory Medicine03 medical and health sciences0302 clinical medicineRecurrencemedicineeducationLymph nodeSurvival analysisNeoplasm metastasieducation.field_of_studyLungbusiness.industryCarcinoid tumormedicine.diseaseClinical trialmedicine.anatomical_structure030220 oncology & carcinogenesisOriginal ArticleNeuroendocrine tumors (NETs)Radiologybusiness
researchProduct

SPET/CT image co-registration in the abdomen with a simple and cost-effective tool

2002

Fusion of morphology and function has been shown to improve diagnostic accuracy in many clinical circumstances. Taking this into account, a number of instruments combining computed tomography (CT) with positron emission tomography (PET) or single-photon emission tomography (SPET) are appearing on the market. The aim of this study was to evaluate a simple and cost-effective approach to generate fusion images of similar quality. For the evaluation of the proposed approach, patients with neuroendocrine abdominal tumours with liver metastases were chosen, since the exact superimposition in the abdomen is more difficult than in other regions. Five hours following the injection of 110 MBq (111)In…

Quality ControlRadiography AbdominalRestraint Physicalmedicine.medical_specialtyImage qualityRadiographySingle-photon emission computed tomographyDigestive System NeoplasmsSensitivity and SpecificityAbdomenHumansMedicineRadiology Nuclear Medicine and imagingTomography Emission-Computed Single-PhotonImage fusionmedicine.diagnostic_testbusiness.industryLiver NeoplasmsSubtractionReproducibility of ResultsGeneral MedicineImage EnhancementNeuroendocrine TumorsPositron emission tomographySubtraction TechniqueTomographyRadiologyTomography X-Ray ComputedbusinessNuclear medicineEmission computed tomographyEuropean Journal of Nuclear Medicine and Molecular Imaging
researchProduct

Ki-67 assessment of pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis of manual vs. digital pathology scoring

2022

Ki-67 assessment is a key step in the diagnosis of neuroendocrine neoplasms (NENs) from all anatomic locations. Several challenges exist related to quantifying the Ki-67 proliferation index due to lack of method standardization and inter-reader variability. The application of digital pathology coupled with machine learning has been shown to be highly accurate and reproducible for the evaluation of Ki-67 in NENs. We systematically reviewed all published studies on the subject of Ki-67 assessment in pancreatic NENs (PanNENs) employing digital image analysis (DIA). The most common advantages of DIA were improvement in the standardization and reliability of Ki-67 evaluation, as well as its spee…

Reproducibility of ResultsBreast NeoplasmsCarcinoid TumorPathology and Forensic MedicinePancreatic Neoplasmsneuroendocrine neoplasms pancreasNeuroendocrine TumorsKi-67 AntigenGastroenteropancreatic Neuroendocrine TumorBiomarkers TumorImage Processing Computer-AssistedHumansGastroenteropancreatic Neuroendocrine Tumor; Cancer; Carcinoid TumorFemaleCell ProliferationCancer
researchProduct

The role of targeted therapy for gastrointestinal tumors

2014

Abstract: Many targeted drugs have been studied to target the molecular pathways involved in the development of gastrointestinal cancers. Anti-VEGF, anti-EGFR agents, and recently also multi-kinase inhibitor regorafenib, have already been available for the treatment of metastatic colorectal cancer patients. To date, Her-2 positive, gastric cancer patients, are also treated with trastuzumab, while the multi-targeted inhibitor, sorafenib, represents the standard treatment for hepatocellular carcinoma patients. Finally, sunitinib and everolimus, have been approved for the treatment of the neuroendocrine gastroenteropancreatic tumors. Actually a great number of further drugs are under preclinic…

SorafenibOncologyVascular Endothelial Growth Factor Amedicine.medical_specialtyReceptor ErbB-2Hepatocellular carcinomaSettore MED/06 - Oncologia Medicamedicine.medical_treatmentAntineoplastic AgentsNeuroendocrine tumorsTargeted therapyTargeted therapychemistry.chemical_compoundNeuroendocrine tumorTrastuzumabInternal medicineRegorafenibmedicineHumansGastrointestinal tumorsMolecular Targeted TherapyProtein Kinase InhibitorsGastrointestinal NeoplasmsEverolimusHepatologySunitinibbusiness.industryColorectal cancer; Gastric cancer; Gastrointestinal tumors; Hepatocellular carcinoma; Neuroendocrine tumors; Targeted therapy; Hepatology; GastroenterologyGastrointestinal tumorGastroenterologyCancermedicine.diseaseColorectal cancerErbB ReceptorsReceptors Vascular Endothelial Growth FactorchemistryHuman medicineNeuroendocrine tumorsbusinessGastric cancermedicine.drug
researchProduct

The association between appendicitis severity and patient age with appendiceal neoplasm histology—a population-based study

2022

Abstract Purpose Recent studies have reported alarming appendiceal tumor rates associated with complicated acute appendicitis, especially in patients presenting with a periappendicular abscess. However, the data on histology of appendiceal tumors among acute appendicitis patients is limited, especially in patient cohorts differentiating between uncomplicated and complicated acute appendicitis. We have previously reported the association of increased appendiceal tumor prevalence with complicated acute appendicitis in this population-based study. The objective of this secondary analysis was to evaluate the association of both appendicitis severity and patient age with appendiceal tumor histol…

UNCOMPLICATED ACUTE APPENDICITISAdultumpilisäketulehdusINTERVAL APPENDECTOMYANTIBIOTIC-THERAPYAdenocarcinoma3121 Internal medicineCONSERVATIVE TREATMENTNeuroendocrine tumorhistologiaMANAGEMENTAppendectomyHumansPseudomyxoma peritoneiINCREASED RISKMETAANALYSISMixed adeno-neuroendocrine carcinomapseudomyxoma peritoneiappendicitis severityappendiceal adenocarcinomaGastroenterologyneuroendokriiniset kasvaimetAppendiceal adenocarcinomaSERIESAppendicitisTUMORSAbscesskarsinoomatAppendiceal Neoplasms3121 General medicine internal medicine and other clinical medicineAcute Diseasemixed adeno-neuroendocrine carcinomaAppendicitis severityGoblet cell carcinomaneuroendocrine tumorgoblet cell carcinoma
researchProduct

New biological aspects of Chromogranin A-derived peptides: Focus on vasostatins

2007

Chromogranin A (CgA), one component of the granin family, represents the major soluble protein co-stored and co-released with catecholamines, within chromaffin cells secretory granules. It is considered a diagnostic and prognostic marker of several diseases, including a variety of tumours and cardiac heart failure. It also represents a precursor of biologically active fragments, generated after proteolytic cleavage at the level of the multiple pairs of dibasic sites which enrich its sequence. CgA, and its derived fragments show an old evolutionary history being ubiquitously present throughout the animal word, from mammals to invertebrates. Their biological functions include control of hormo…

endocrine systemPhysiologyMolecular Sequence DataBiologyModels BiologicalBiochemistryParacrine signallingChromogranine AAnimalsHumansAmino Acid SequenceAutocrine signallingMolecular BiologyPeptide sequencePhylogenyInnate immune systemSettore BIO/16 - Anatomia UmanaGraninChromogranin APeptide FragmentsBiochemistrybiology.proteinChromogranin AParathyroid hormone secretionNeuroendocrine tumorsCalreticulinHomeostasisComparative Biochemistry and Physiology Part A: Molecular & Integrative Physiology
researchProduct